[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200870454A1 - Способ ингибирования c-kit киназы - Google Patents

Способ ингибирования c-kit киназы

Info

Publication number
EA200870454A1
EA200870454A1 EA200870454A EA200870454A EA200870454A1 EA 200870454 A1 EA200870454 A1 EA 200870454A1 EA 200870454 A EA200870454 A EA 200870454A EA 200870454 A EA200870454 A EA 200870454A EA 200870454 A1 EA200870454 A1 EA 200870454A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibiting
kit
subject
compound
kit kinase
Prior art date
Application number
EA200870454A
Other languages
English (en)
Other versions
EA016611B1 (ru
Inventor
Рене Л. Дежарле
Кристофер Дж. Моллой
Карл Л. Менти
Карл Р. Иллиг
Шелли К. Баллентайн
Цзиньшэн Чэнь
Санатх К. Мигалла
Марк Дж. Уолл
Кеннет Дж. Уилсон
М. Джонатан Рудольф
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of EA200870454A1 publication Critical patent/EA200870454A1/ru
Publication of EA016611B1 publication Critical patent/EA016611B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Способ снижения или ингибирования киназной активности С-KIT в клетке или у субъекта и применение такого соединения для профилактики или лечения у субъекта клеточно-пролиферативного расстройства и/или расстройств, связанных с С-KIT, с использованием соединения по настоящему изобретению (формула (I)) или его сольвата, гидрата, таутомера или фармацевтически приемлемой соли. Настоящее изобретение также направлено на способы лечения состояний, таких как различные типы рака и другие клеточно-пролиферативные расстройства.
EA200870454A 2006-04-20 2007-04-19 Способ лечения мастоцитоза EA016611B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79347106P 2006-04-20 2006-04-20
PCT/US2007/066985 WO2007124369A2 (en) 2006-04-20 2007-04-19 Method of inhibiting c kit kinase

Publications (2)

Publication Number Publication Date
EA200870454A1 true EA200870454A1 (ru) 2009-04-28
EA016611B1 EA016611B1 (ru) 2012-06-29

Family

ID=38625740

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870454A EA016611B1 (ru) 2006-04-20 2007-04-19 Способ лечения мастоцитоза

Country Status (22)

Country Link
EP (2) EP2397138B1 (ru)
JP (1) JP5595727B2 (ru)
KR (1) KR101448052B1 (ru)
CN (2) CN102670605B (ru)
AU (1) AU2007240400B2 (ru)
BR (1) BRPI0710542B8 (ru)
CA (1) CA2649755C (ru)
CO (1) CO6382175A2 (ru)
CR (1) CR10450A (ru)
EA (1) EA016611B1 (ru)
EC (1) ECSP088842A (ru)
ES (2) ES2389678T3 (ru)
GT (1) GT200800225A (ru)
HK (1) HK1124766A1 (ru)
IL (1) IL194846A (ru)
MX (1) MX2008013528A (ru)
MY (1) MY147226A (ru)
NO (1) NO342001B1 (ru)
NZ (1) NZ572200A (ru)
SG (1) SG171592A1 (ru)
WO (1) WO2007124369A2 (ru)
ZA (1) ZA200809874B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012288900B2 (en) 2011-07-27 2016-10-06 Ab Science Selective protein kinase inhibitors
CN104370880A (zh) * 2013-01-24 2015-02-25 韩冰 一类蛋白酶抑制剂及其制备方法和用途
KR102295416B1 (ko) 2013-07-22 2021-08-30 이도르시아 파마슈티컬스 리미티드 1-(피페라진-1-일)-2-([1,2,4]트리아졸-1-일)-에타논 유도체
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
KR101967083B1 (ko) 2015-01-15 2019-04-08 이도르시아 파마슈티컬스 리미티드 Cxcr3 수용체 조절제로서의 히드록시알킬-피페라진 유도체
CN105753770A (zh) * 2015-05-27 2016-07-13 上海佐林生物医药有限公司 蛋白激酶抑制剂制备方法、中间体、制备方法及应用
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT627940E (pt) 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
BR0010017A (pt) 1999-04-28 2002-06-11 Univ Texas Composições e processos para o tratamento de câncer por inibição seletiva de vegf
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
ATE375342T1 (de) * 2002-08-02 2007-10-15 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren
ATE465731T1 (de) * 2003-10-23 2010-05-15 Ab Science 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
AU2005209485A1 (en) * 2004-01-30 2005-08-11 Ab Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
CA2585053C (en) * 2004-10-22 2011-07-12 Janssen Pharmaceutica N.V. Substituted n-acyl (hetero)aryl compounds as c-fms kinase inhibitors
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
BRPI0617489A2 (pt) * 2005-10-18 2011-07-26 Janssen Pharmaceutica Nv compostos, composiÇço e uso de ditos compostos para inibir a flt3 cinase
AU2006342509A1 (en) * 2006-04-20 2007-11-01 Janssen Pharmaceutica, N.V. c-fms kinase inhibitors
US8815867B2 (en) * 2006-04-20 2014-08-26 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase
US7414050B2 (en) * 2006-04-20 2008-08-19 Janssen Pharmaceutica, N.V. Inhibitors of c-fms kinase

Also Published As

Publication number Publication date
NO342001B1 (no) 2018-03-12
SG171592A1 (en) 2011-06-29
IL194846A (en) 2015-07-30
CN101610768A (zh) 2009-12-23
CA2649755C (en) 2014-12-02
CO6382175A2 (es) 2012-02-15
IL194846A0 (en) 2009-08-03
AU2007240400A1 (en) 2007-11-01
EA016611B1 (ru) 2012-06-29
WO2007124369A3 (en) 2008-03-06
CN101610768B (zh) 2012-03-21
CN102670605B (zh) 2015-07-29
WO2007124369A2 (en) 2007-11-01
ZA200809874B (en) 2010-02-24
CN102670605A (zh) 2012-09-19
EP2015748B1 (en) 2012-07-04
JP5595727B2 (ja) 2014-09-24
CA2649755A1 (en) 2007-11-01
EP2015748A2 (en) 2009-01-21
ES2389678T3 (es) 2012-10-30
ECSP088842A (es) 2008-11-27
NO20084892L (no) 2009-01-06
JP2009534418A (ja) 2009-09-24
BRPI0710542A2 (pt) 2012-06-05
ES2458291T3 (es) 2014-04-30
EP2397138B1 (en) 2013-12-11
HK1124766A1 (en) 2009-07-24
GT200800225A (es) 2009-05-15
NZ572200A (en) 2011-09-30
CR10450A (es) 2009-02-23
MX2008013528A (es) 2008-10-29
EP2397138A1 (en) 2011-12-21
AU2007240400B2 (en) 2013-08-22
BRPI0710542B8 (pt) 2021-05-25
BRPI0710542B1 (pt) 2021-01-12
KR101448052B1 (ko) 2014-10-07
MY147226A (en) 2012-11-14
KR20080111545A (ko) 2008-12-23

Similar Documents

Publication Publication Date Title
WO2007048088A3 (en) Method of inhibiting flt3 kinase
EA200870454A1 (ru) Способ ингибирования c-kit киназы
PH12018500792A1 (en) Benzolactam compounds as protein kinase inhibitors
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
TW200720268A (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
IN2014KN02886A (ru)
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
MX2009011810A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
MX2009012719A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
MX2009013077A (es) Derivados dde benzoxazolona.
SI2054418T1 (sl) Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2010004967A (es) Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso.
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
TW200503722A (en) Substituted 7-aza-quinazoline compounds
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors
UA105483C2 (ru) Производные изохинолинона, композиция на их основе и применение в качестве ингибиторов pi3k
NZ630353A (en) Pyrazolopyrimidines and related heterocycles as ck2 inhibitors